Tags: Drug.

Pruvanserin (EMD-281014 LY-2422347) is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company’s development pipeline. In addition to its sleep-improving properties pruvanserin has also been shown to have antidepressant anxiolytic and working memory-enhancing effects in animal studies.

Pruvanserin.png
ATC prefix
none
CAS number
443144-26-1
CAS supplemental
443144-27-2 (hydrochloride)
FDA UNII code
UL09X1D9EM
IUPAC name
7-(4-[2-(4-fluorophenyl)ethyl]piperazin-1-ylcarbonyl)-1H-indole-3-carbonitrile
PubChem
6433122

Loading...

This page contains content from the copyrighted Wikipedia article "Pruvanserin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.